Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Coffey, Kelly ^a   Blackburn, Timothy J ^a,c   Cook, Susan ^a   Golding, Bernard T ^a,c   Griffin, Roger J ^a,c   Hardcastle, Ian R ^a,c   Hewitt, Lorraine ^a   Huberman, Kety ^b   McNeill, Hesta V ^a   Newell, David R ^a   Roche, Celine ^a,c   Ryan Munden, Claudia A ^a   Watson, Anna ^a,c   Robson, Craig N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b OSI PHARMACEUTICALS INC   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(ISOTHIAZOL 5 YL)DISULFANE; 2 BROMO 3 METHYLTHIOPHENE; 2,2' DITHIO(BIS)BENZOTHIAZOLE; 2,2' DITHIODIPYRIDINE; 4 METHYL 5 BROMOISOTHIAZOLE; 4 METHYL 5 THIOACYANATOISOTHIAZOLE; 4 METHYLISOTHIAZOLE; 4,4' DITHIODIPYRIDINE; 5 THIOACYANATOISOTHIAZOLE; ALPHA TUBULIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ATM PROTEIN; CASPASE 3; CASPASE 9; DIPHENYL DISULPHIDE; HISTONE ACETYLTRANSFERASE; HISTONE GAMMA H2AX; HISTONE H2AX; HISTONE H3; HISTONE H4; ISOTHIAZOLE DERIVATIVE; NU 9056; OXA 10; P300 HISTONE ACETYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21; PROTEIN P53; TIP60 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETYLATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IONIZING RADIATION; MALE; PROSTATE CANCER; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

ACETYLATION; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; HEK293 CELLS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RADIATION, IONIZING; RNA INTERFERENCE; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84867325687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045539     Document Type: Article

References (39)

1. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, et al. (2010) TRIM24 links a non-canonical histone signature to breast cancer. Nature 468: 927-932.
2. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, et al. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841-851.
3. Tang Y, Luo J, Zhang W, Gu W, (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839.
4. Sun Y, Jiang X, Chen S, Fernandes N, Price BD, (2005) A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci U S A 102: 13182-13187.
5. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, et al. (2002) Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22: 3373-3388.
6. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN, (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277: 25904-25913.
7. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, et al. (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147: 507-514.
8. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, et al. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27: 5410-5417.
9. Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G, (1996) Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216: 357-366.
10. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, et al. (2002) Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110: 55-67.
11. Gavaravarapu S, Kamine J, (2000) Tip60 inhibits activation of CREB protein by protein kinase A. Biochem Biophys Res Commun. 269: 758-766.
12. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, et al. (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275: 20853-20860.
13. Fu M, Rao M, Wang C, Sakamaki T, Wang J, et al. (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23: 8563-8575.
14. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, et al. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22: 2466-2477.
15. Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, et al. (2005) Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 434: 921-926.
16. Gorrini C, Squatrito M, Luise C, Syed N, Perna D, et al. (2007) Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063-1067.
17. Culig Z, Bartsch G, (2006) Androgen axis in prostate cancer. J Cell Biochem 99: 373-381.
18. Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, et al. (2000) HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5: 589-595.
19. Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A, (2004) Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl 43: 3974-3976.
20. Mai A, Cheng D, Bedford MT, Valente S, Nebbioso A, et al. (2008) epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem 51: 2279-2290.
21. Sbardella G, Castellano S, Vicidomini C, Rotili D, Nebbioso A, et al. (2008) Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg Med Chem Lett 18: 2788-2792.
22. Dekker FJ, Ghizzoni M, van der Meer N, Wisastra R, Haisma HJ, (2009) Inhibition of the PCAF histone acetyl transferase and cell proliferation by isothiazolones. Bioorg Med Chem 17: 460-466.
23. Gorsuch S, Bavetsias V, Rowlands MG, Aherne GW, Workman P, et al. (2009) Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). Bioorg Med Chem 17: 467-474.
24. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, et al. (2005) Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 4: 1521-1532.
25. Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, et al. (2000) Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102: 463-473.
26. Kimura A, Horikoshi M, (1998) Tip60 acetylates six lysines of a specific class in core histones in vitro. Genes Cells 3: 789-800.
27. Yamamoto T, Horikoshi M, (1997) Novel substrate specificity of the histone acetyltransferase activity of HIV-1-Tat interactive protein Tip60. J Biol Chem 272: 30595-30598.
28. Lin X, Asgari K, Putzi MJ, Gage WR, Yu X, et al. (2001) Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res 61: 8611-8616.
29. Park KC, Park EJ, Kim ER, Kim Y, Chung SH, et al. (2005) Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-induced arthritis in rabbits. Biochem Biophys Res Commun 331: 1469-1477.
30. Sharma GG, So S, Gupta A, Kumar R, Cayrou C, et al. (2010) MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol 30: 3582-3595.
31. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, et al. (1999) Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274: 17599-17604.
32. Ikura T, Tashiro S, Kakino A, Shima H, Jacob N, et al. (2007) DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol Cell Biol 27: 7028-7040.
33. Gaughan L, Logan IR, Neal DE, Robson CN, (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33: 13-26.
34. Li M, Luo J, Brooks CL, Gu W, (2002) Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 277: 50607-50611.
35. Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J,et al. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 70: 540-554.
36. Rigas AC, Robson CN, Curtin NJ, (2007) Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 26: 7611-7619.
37. Bannister AJ, Kouzarides T, (1996) The CBP co-activator is a histone acetyltransferase. Nature 384: 641-643.
38. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
39. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, et al. (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16: 2344-2351.